Wayne Hockmeyer - GenVec Chairman of the Board
Chairman
Dr. Wayne T. Hockmeyer, Ph.D., is Chairman of the Board of Genvec, Inc. Dr. Hockmeyer founded MedImmune, Inc. in April 1988 as President and Chief Executive Officer and was elected a director of MedImmune in May 1988. Dr. Hockmeyer became Chairman of the board of directors of MedImmune in May 1993 and left his position as Chief Executive Officer in October 2000. Dr. Hockmeyer is currently retired, having resigned from his positions as a member of the MedImmune board of directors and as President of MedImmune Ventures, Inc. following the acquisition of MedImmune by AstraZeneca Biopharmaceuticals, Inc. in June 2007 since 2013.
Age | 70 |
Tenure | 11 years |
Professional Marks | Ph.D |
Phone | 240-632-0740 |
Web | http://www.genvec.com |
GenVec Management Efficiency
The company has return on total asset (ROA) of (86.26) % which means that it has lost $86.26 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (248.11) %, meaning that it created substantial loss on money invested by shareholders. GenVec's management efficiency ratios could be used to measure how well GenVec manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
Found 7 records | CHAIRMAN Age | ||
Shao Xu | Kingdee International Software | 60 | |
Randall Fields | Park City Group | 77 | |
Najeeb Ghauri | NetSol Technologies | 70 | |
Kendall Larsen | VirnetX Holding Corp | 67 | |
John Watkins | Park City Group | N/A | |
R Seale | Q2 Holdings | 52 | |
Robert Seale | Q2 Holdings | 57 |
Management Performance
Return On Equity | -248.11 | |||
Return On Asset | -86.26 |
GenVec Inc Leadership Team
Elected by the shareholders, the GenVec's board of directors comprises two types of representatives: GenVec inside directors who are chosen from within the company, and outside directors, selected externally and held independent of GenVec. The board's role is to monitor GenVec's management team and ensure that shareholders' interests are well served. GenVec's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, GenVec's outside directors are responsible for providing unbiased perspectives on the board's policies.
Douglas Swirsky, President CEO, Director | ||
Stefan Loren, Director | ||
Wayne Hockmeyer, Chairman of the Board | ||
Quinterol Mallette, Director | ||
Douglas Brough, Chief Scientific Officer | ||
William Kelley, Independent Director | ||
Marc Schneebaum, Independent Director | ||
Michael Richman, Director | ||
Rena Cohen, IR Contact Officer | ||
Bryan Butman, Sr. VP of Devel. | ||
James Lambert, Sr. Director of Accounting and Fin., Treasurer and Corporate Controller |
GenVec Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is GenVec a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Return On Equity | -248.11 | |||
Return On Asset | -86.26 | |||
Current Valuation | 25.09 M | |||
Shares Outstanding | 2.27 M | |||
Shares Owned By Insiders | 3.97 % | |||
Shares Owned By Institutions | 32.70 % | |||
Number Of Shares Shorted | 250.07 K | |||
Price To Earning | (1.94) X | |||
Price To Book | 26.25 X | |||
Price To Sales | 48.80 X |
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards GenVec in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, GenVec's short interest history, or implied volatility extrapolated from GenVec options trading.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in real. You can also try the Stocks Directory module to find actively traded stocks across global markets.
Other Consideration for investing in GenVec Stock
If you are still planning to invest in GenVec Inc check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the GenVec's history and understand the potential risks before investing.
Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities |